Compare National Beverage Corp. (FIZZ) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Tango Therapeutics Inc. — how do they compare? National Beverage Corp. trades at $33.54 (market cap $3.14B), while Tango Therapeutics Inc. trades at $22.3 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and National Beverage Corp. is more actively traded (359,096 versus 3,438,781). Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 32 Days and Tango Therapeutics Inc. for 0 Days on average.
| FIZZ | TNGX | |
|---|---|---|
Market Cap | $3.14B | $3.74B |
Volume | 359,096 | 3,438,781 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $32.90 |
52-Week Low | $29.20 | $7.50 |
Typical Hold Time | 32 Days | 0 Days |
Enterprise Value | $3.09B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
National Beverage Corp. (FIZZ) trades at $32.99, up 2.61% today, with a bullish technical signal from moving averages despite recent earnings misses. The company maintains strong profitability with 36.21% gross margins and 40.13% ROE, though revenue growth has stalled at $1.2B annually. Recent Q1 2027 results showed the first year-over-year revenue growth since Q1 2026 but with margin pressure from input costs.
FIZZ faces mixed sentiment with 50% analyst sell ratings against bullish technical indicators. The stock offers strong profitability metrics but faces growth challenges and margin compression risks from tariffs and rising costs. Institutional buying continues despite earnings volatility, suggesting long-term confidence in the business model.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
